Alcidion (ASX:ALC) has raised funds via a placement
Alcidion Group Ltd. has raised funds to accelerate its growth strategy.
Alcidion is transforming healthcare with smart, intuitive technology solutions that provide real-time clinical decision support. It integrates with EMR providers and assists doctors and nurses, covering functions such as streamlining patient journeys, smart analytics to help with clinical decisions, improving patient safety, increasing productivity amongst clinical staff through messaging applications, and data capture and interpretation.
Oaklins’ team in Australia acted as Alcidion’s lead manager to raise money via an institutional placement.
Talk to the deal team
Related deals
Xiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn moreTekova Oyj has completed a technical listing on the Nasdaq First North Growth Market Finland
Tekova Oyj has successfully completed a technical listing (IPO) on the Nasdaq First North Growth Market Finland. This transaction marks a significant milestone in the company’s growth strategy, enhancing its visibility and access to capital markets.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn more